Cimzia and Sarilumab Prefilled Pens
Determining the interaction of Cimzia and Sarilumab Prefilled Pens and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Using sarilumab together with certolizumab may increase the risk of serious and potentially life-threatening infections. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact. Contact your doctor immediately if you develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:GENERALLY AVOID: Coadministration of interleukin-6 (IL-6) inhibitors with other biologic disease-modifying antirheumatic drugs (DMARDs) may result in increased immunosuppression and a greater risk of infection. Treatment with IL-6 inhibitors has been associated with serious, potentially life-threatening and fatal infections, including tuberculosis, invasive fungal infections such as candidiasis, aspergillosis and pneumocystis, and other opportunistic infections. Cases have occurred mostly in patients receiving concomitant immunosuppressants like methotrexate or corticosteroids. Use of IL-6 inhibitors in combination with biologic DMARDs such as tumor necrosis factor (TNF) blockers, IL-1R antagonists, anti-CD20 monoclonal antibodies, or T-cell costimulation modulators has not been studied. There may be an increased risk of neutropenia and infections during treatment with IL-6 inhibitors in patients who were previously exposed to TNF antagonists.
MANAGEMENT: Concomitant use of IL-6 inhibitors with other biologic DMARDs should be avoided.
- "Product Information. Kevzara (sarilumab)." sanofi-aventis, Bridgewater, NJ.
- "Product Information. Remicade (infliximab)." Centocor Inc, Malvern, PA.
- "Product Information. Simponi (golimumab)." Centocor Inc, Malvern, PA.
- "Product Information. Humira (adalimumab)." Abbott Pharmaceutical, Abbott Park, IL.
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- "Product Information. Enbrel (etanercept)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
- Cerner Multum, Inc. "Australian Product Information." O 0
- "Product Information. Actemra (tocilizumab)." Genentech, South San Francisco, CA.
- "Product Information. Cimzia (certolizumab)." UCB Pharma Inc, Smyrna, GA.
Generic Name: sarilumab
Brand name: Kevzara, Kevzara Pre-filled Pen
Synonyms: Sarilumab
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Cimzia-Sarilumab Prefilled Syringes
- Cimzia-Sarilumab Subcutaneous
- Cimzia-Sarna Hc Topical application
- Cimzia-Sarnol-HC
- Cimzia-Sarnol-HC Maximum Strength
- Cimzia-SAStid
- Sarilumab Prefilled Pens-Cimzia (Certolizumab Prefilled Syringes)
- Sarilumab Prefilled Pens-Cimzia (Certolizumab Vials)
- Sarilumab Prefilled Pens-Cinacalcet
- Sarilumab Prefilled Pens-Cinacalcet Hydrochloride
- Sarilumab Prefilled Pens-Cinobac
- Sarilumab Prefilled Pens-Cinolar